Smurfit WestRockの空売り状況は、投資家がSmurfit WestRockの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Smurfit WestRock (NYSE:SW) 株価情報, 空売り情報

Smurfit WestRock

Smurfit WestRock manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. After the merger of Smurfit Kappa and WestRock in summer 2024, Smurfit WestRock became the largest producer of containerboard in the world, with substantial operations in North America, South America, and Europe.

Smurfit WestRock PLC

SRISAWAD CRP PCL FRGN SHS by Srisawad Corp Pub Co Ltd.

Stran & Co Inc

Amplify ETF Trust Amplify BlackSwan Growth & Treasury Core ETF

TrustSwap

Swash

SHOCKWAVE MED INC

Smith & Wesson Brands, Inc. - Common Stock

Smith & Wesson Brands Inc

SOUTHWEST CASINO CORP by Southwest Casino Corp.

Southwest Casino Corp

SUNWAY CONSTR GRP by SUNWAY CONSTR GROUP BHD

SWCC Corp

SOFTWARE AG by Software AG

Swedbank AB

Swedencare AB

SKYWORTH GROUP LTD by Skyworth Group Limited

Skyworth Group Ltd

SKYWORTH GRP LTD UNSP/ADR by Skyworth Group Limited

SWEAT - United States Dollar

SWEEGEN INC by SweeGen, Inc.

Swell - United States Dollar

Swell Ethereum - United States Dollar

SwiftCoin - United States Dollar

SWATCH GROUP AG NEW ORD by Swatch Group AG

The Swatch Group AG

SWATCH GROUP AG UNSP/ADR by Swatch Group AG

SAWAI GROUP HLDGS CO LTD by SAWAI GROUP HLDGS CO LTD.

Sawai Group Holdings Co Ltd

STAR WEALTH GROUP INC by Star Wealth Group Inc.

SUMITOMO WAREHOUSE CO by Sumitomo Warehouse Co. Ltd.

Sumitomo Warehouse Co Ltd

SOLARWINDS INC COM

Latham Group Inc

Solowin Holdings - Class A Ordinary Share

Solowin Holdings Ltd

Swingby

Southwest Iowa Renewable Energy LLC Units Series -A-

Southwest Iowa Renewable Energy LLC

SEKUR PRIVATE DATA LTD by SEKUR PRIVATE DATA LTD.

Sekur Private Data Ltd

Stanley Black & Decker, Inc. Common Stock

Stanley Black & Decker Inc

SWK Holdings Corp

SWK Holdings Corporation - 9.00% Senior Notes due 2027

Skyworks Solutions Inc

SILVER WOLF EXPLORATION by Silver Wolf Exploration Ltd.

Silver Wolf Exploration Ltd

Swedish Match AB ADR

STARWIN MEDIA HLDGS INC by Starwin Media Holdings, Inc.

Starwin Media Holdings Inc

Swarmio Media Holdings Inc

Southwestern Energy Company COM

Miratap Inc

EDM Resources Inc

SWSTRN MEDICAL SLTNS INC by Southwestern Medical Solutions, Inc.

Southwestern Medical Solutions Inc

SWEDISH ORPHAN BIO U/ADR by Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

SOFTWAREONE HLDG AG by SOFTWAREONE HLDG AG

SoftwareONE Holding AG

Swop

SWP Growth & Income ETF

Kava Swap

SWIRE PROPERTIES LTD ORD by Swire Properties Ltd.

Swire Properties Ltd

SWIRE PROPERTIS UNSP/ADR by Swire Properties Ltd.

SWISS PRIME SITE AG U/ADR by Swiss Prime Site AG

Swiss Prime Site AG

SWOOP HOLDINGS LTD by Swoop Holdings Ltd.

Swoop Holdings Ltd

SWISS PRIME SITE AG by Swiss Prime Site AG

SHOWA PAXXS CORP TOKYO by SHOWA PAXXS CORP

SWISSQUOTE GROUP HOLDING by Swissquote Group Holding AG

Swissquote Group Holding SA

SWIRE PACIFIC LTD A by Swire Pacific Ltd.

Swire Pacific Ltd

SWIRE PAC LTD A S/ADR by Swire Pacific Ltd.

SWIRE PACIFIC LTD B ORD by Swire Pacific Ltd.

SWIRE PACIFIC LTD B S/ADR by Swire Pacific Ltd.

SHIBUSAW LOGISTICS CORP by SHIBUSAW LOGISTICS CORP

Shibusawa Logistics Corp

SEAWRIGHT HOLDINGS INC by Seawright Holdings, Inc.

Seawright Holdings Inc

U-Swirl Inc

AppSwarm Corp

Swerve

SWISS LIFE HOLDING AG by Swiss Life Holding

Swiss Life Holding AG

CLEAN ENGY SPCL SITUTINS by Clean Energy Special Situations Corp.

Clean Energy Special Situations Corp

SWISS WTR DECAF COFFEE by Swiss Wtr Decaffinated Coffee Inc.

Swiss Water Decaffeinated Coffee Inc

Clean Energy Special Situations Corp Units (1 Ord & 1/2 War)

Clean Energy Special Situations Corp Warrants (01/12/2027)

Carbon

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics Inc

Swvl Holdings Corp

SIMON WORLDWIDE INC by Simon Worldwide, Inc.

Simon Worldwide Inc

Southwest Gas Holdings, Inc. Common Stock (DE)

Southwest Gas Holdings Inc

Sanoma Oyj

STORNOWAY DIAMOND CORP by Stornoway Diamond Corp.

Stornoway Diamond Corp

Total Return Securities Fund Common Stock

Swiss Helvetia Fund Inc

Swisscom AG

SCHWEIZERISCHE NATLBANK by Schweizerische Nationalbank

Schweizerische Nationalbank

NT219 is a novel small molecule designed to target two key oncogenic pathways: IRS1/2 (Insulin Receptor Substrates 1 and 2) and STAT3 (Signal Transducer and Activator of Transcription 3).&nbsp; NT219 induces the degradation of IRS1/2 and inhibits the phosphorylation of STAT3, thereby, blocking their respective signaling pathways. The Phase 2 study will evaluate NT219 in combination with either pembrolizumab (KEYTRUDA&#xAE;) or cetuximab, both of which are standard-of-care treatments in R/M SCCHN patients. Additionally, the study aims to evaluate potential biomarkers identified in a previous clinical study of NT219.

Biotech

Health Care

General

PPBT

Purple Biotech Initiated Phase 2 Study Evaluating NT219 In Patients With Recurrent And/Or Metastatic Squamous Cell Carcinoma Of The Head And Neck

Kamada Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that, while circumstances in the Middle East are evolving, the Company is continuing the operations and manufacturing at its Israeli facility focusing on business continuity, and based on its assessment, the global availability of its products is not expected to be interrupted.
"While events in the Middle East are evolving, the operations and ongoing manufacturing of our products continue as planned," said Amir London, Kamada's Chief Executive Officer. "Although our shipments from Israel may be temporarily affected by the current closing of the Israeli airspace, our distribution centers outside Israel, as well as our partners and distributors worldwide, have sufficient level of products available, and we do not foresee shortage in meeting client demands. We are focused on our business continuity and the well-being of all our employees and will continue to closely monitor the circumstances."

News

KMDA

Kamada Assures Uninterrupted Drug Supply as Israeli Operations Continue Despite Middle East Tensions

Events

SKYE

Skye Bioscience To Present At American Diabetes Association's 85th Scientific Sessions On Jun. 22

Back in 1996, Microsoft CEO Bill Gates reviewed a book called Warren Buffett: The Making of an American Capitalist by Roger Lowenstein, where he shared the lessons ‘Oracle of Omaha' Berkshire Hathaway CEO Warren Buffett, taught him.
What Happened: Writing <a href="https://hbr.org/1996/01/what-i-learned-from-warren-buffett">for</a> the Harvard Business Review, Gates remembered his first meeting with Buffett in July 1991. "I was extremely skeptical when my mother suggested I take a day away from work to meet him," Gates wrote.
"What were he and I supposed to talk about, P/E ratios? I mean, spend all day with a guy who just picks stocks? Especially when there's lots of work to do? Are you kidding?" he recalled thinking.
His mother's insistence eventually pushed Gates to agree to attend the gathering Buffett was part of. "He asked good questions and told educational stories," Gates wrote. "There's nothing I like so much as learning, and I had never met anyone who thought about business in such a clear way."
As their acquaintance continued, Gates was particularly impressed by <a href="https://www.benzinga.com/general/education/25/05/45602754/warren-buffett-investment-success-3-simple-rules-to-copy-oracle-of-omaha">Buffett's investing philosophy</a>. As Buffett once wrote, "Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results." 
"Warren never makes an investment where the difference between doing it and not doing it relies on the second digit of computation," Gates explained. "He doesn't invest—take a swing of the bat—unless the opportunity appears unbelievably good."
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45940555/naval-ravikant-says-elon-musks-a-purist-recalling-why-he-likely-never-speaks-to-bill-gates">Naval Ravikant Says Elon Musk&#8217;s A &#8216;Purist&#8217; Recalling Why He Likely Never Speaks To Bill Gates</a>
Why It Matters: Buffett's habit of sticking to what he knows well, reading extensively, and saying no to distractions was influential for Gates. "He knows what he likes to do—and what he does, <a href="https://www.benzinga.com/25/04/44855242/charlie-munger-once-highlighted-how-warren-buffetts-lifelong-learning-made-berkshire-hathaways-success-possible-and-the-crucial-lesson-you-can-take-from-it">he does unbelievably well</a>," Gates observed.
One quote in particular stood out to Gates: "You should invest in a business that even a fool can run, because someday a fool will." This bit of wisdom shaped Gates's perspective on management and risk.
Buffett also challenged Gates to be more creative with his thinking, once using a set of nontransitive dice to demonstrate a counterintuitive truth in probability. "It was counterintuitive, like a lot of things in the business world."
Gates also highlighted Buffett's parenting approach: "<a href="https://www.benzinga.com/personal-finance/25/04/44889632/warren-buffetts-son-cashed-in-90k-instead-of-waiting-on-500-million-now-hes-using-buffett-bucks-to-build-his-own-dream-town-in-new-york">He wants to give his children enough money for them to do anything</a> but <a href="https://www.benzinga.com/personal-finance/25/04/44657074/warren-buffetts-kid-says-they-had-to-pull-their-own-weight-if-you-went-to-the-movies-you-never-knew-if-he-would-buy-your-ticket-or-not">not enough for them to do nothing</a>." That statement "crystallized my feelings," Gates admitted.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45938365/trumps-1000-baby-account-aligns-with-billionaire-investor-warren-buffetts-start-young-philosophy">Trump&#8217;s $1,000 Baby Account Aligns With Billionaire Investor Warren Buffett&#8217;s &#8216;Start Young&#8217; Philosophy</a></li>
</ul>
Photo courtesy: mark reinstein / Shutterstock.com

Equities

Bill Gates Once Scoffed, 'Spend All Day With A Guy Who Just Picks Stocks?'—Before Discovering That The 'Stock Picker' Had A Mastermind's Blueprint For Winning In Business

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aldeyra.com%2F&amp;esheet=54276760&amp;newsitemid=20250617568242&amp;lan=en-US&amp;anchor=Aldeyra+Therapeutics%2C+Inc.&amp;index=1&amp;md5=7935efc7409c924962b58b43bc4b8f61">Aldeyra Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. Per FDA agreement, the only new clinical data included in the resubmitted NDA were from the recently completed dry eye chamber trial, which achieved the primary endpoint.
"Consistent with a number of clinical trials that suggest the potential of reproxalap to rapidly improve the symptoms of dry eye disease, we believe the clinical trial results included in the resubmission announced today are robust," stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. "Based on the lack of notable baseline differences across treatment arms and the highly statistically significant achievement of the prespecified primary endpoint in favor of reproxalap over vehicle, in conjunction with recent FDA discussions, we believe that previous concerns raised by the FDA have been addressed."
In April 2025, Aldeyra received a Complete Response Letter from the FDA that stated that potential methodological issues in a previously completed dry eye chamber trial, including a baseline difference across treatment arms, may have affected the interpretation of the results; the letter stated that an additional symptom trial would be required for resubmission. In May 2025, Aldeyra announced the achievement of the primary endpoint (P=0.002) in a Phase 3 randomized, double‑masked, vehicle‑controlled dry eye chamber trial that assessed the activity of reproxalap in reducing ocular discomfort, an FDA‑accepted symptom of dry eye disease. No notable differences in baseline scores across treatment arms were observed in the clinical trial, and no safety concerns were identified. Consistent with prior clinical trials, the most common adverse event was mild and transient instillation site discomfort, which most commonly lasted less than one minute.
The Prescription Drug User Fee Act target guidelines for NDA resubmissions include acknowledgment of acceptance for review within 30 days of submission, and completion of submission review within 6 months.

Government

Regulations

ALDX

Aldeyra Resubmits Eye Drug for FDA Review After New Trial Clears Key Hurdle in Treating Dry Eye

Stock Split

UNCY

Unicycive Therapeutics Will Implement A 1-for-10 Reverse Split, Effective On June 20, 2025

<ul>
<li>As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of&nbsp;C. difficile&nbsp;infection (CDI) recurrence through one month after EOT</li>
<li>In contrast, 2 of 14 (14%) patients treated with the standard of care, oral&nbsp;vancomycin, experienced recurrent infection within one month after EOT</li>
<li>When Phase 2b results are combined with Phase 2a results, 25 of 25 (100%)&nbsp;ibezapolstat-treated patients with CDI who had CC at EOT remained recurrence-free through 1 month after EOT; additionally, all 5 Phase 2b ibezapolstat-treated patients observed for up to 3 months following CC experienced no recurrence of infection</li>
</ul>

ACXP

Acurx Pharmaceuticals Announces Publication Of Results In Lancet Of Its Phase 2 Ibezapolstat  Study

Beneficient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) ("Beneficient," "Ben" or the "Company"), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, today announced that the Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") has approved the previously disclosed settlement agreement resolving all claims pending in the Bankruptcy Court under the previously disclosed lawsuits relating to GWG Holdings, Inc. ("GWG" and such litigation, the "GWG Litigation") against the Company, its subsidiaries, and each of their current and former directors and officers (the "Beneficient Parties"). The settlement agreement remains subject to the approval of the District Court for the Northern District of Texas (the "Northern District Court").
As previously announced on March 10, 2025, the Company entered into a binding settlement agreement to resolve all claims in the GWG Litigation for a sum within applicable insurance policy limits. With the Bankruptcy Court's approval, the settlement in the Bankruptcy Court is now final, subject to a 14-day period to appeal. The settlement resolves all claims filed in the Bankruptcy Court against the Beneficient Parties without any admission, concession or finding of any fault, liability or wrongdoing by the Company or any defendant.

Legal

BENF

Beneficient Gets Court Approval to Settle GWG Lawsuit, Clearing Major Legal Hurdle

Canaccord Genuity analyst William Plovanic initiates coverage on Artivion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) with a Buy rating and announces Price Target of $35.

Price Target

Initiation

Analyst Ratings

AORT

Canaccord Genuity Initiates Coverage On Artivion with Buy Rating, Announces Price Target of $35

On Monday, June 16, U.S. markets ended higher on hopes of easing tensions between Israel and Iran, which drove oil prices lower, easing inflation concerns. Hopes for a ceasefire and Iran&#8217;s diplomatic outreach lifted investor sentiment. Tech and communication stocks led gains, while utilities underperformed.
With key economic data and earnings ahead, all eyes remain on the Fed&#8217;s rate decision, with no cuts expected.
In economic data, the New York Empire State Manufacturing Index dropped to -16 in June, down from -9.2 in May and below the expected -5.5.
Most S&amp;P 500 sectors rose Monday, led by tech, communication, and consumer stocks, while utilities and health care declined. The Dow closed higher by 0.75% at 42,515.09, the S&amp;P 500 gained 0.94% to 6,033.11, and the Nasdaq rose 1.52% to 19,701.21.
Related: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/06/45968002/trump-says-israel-iran-ceasefire-not-on-the-table-left-g7-early-for-a-much-bigger-reason-spy-qqq-dip-in-premarket-oil-climbs" rel="noreferrer noopener">Trump Says Israel-Iran &#8216;Ceasefire&#8217; Not On The Table, Left G7 Early For A &#8216;Much Bigger&#8217; Reason: SPY, QQQ Dip In Premarket, Oil Climbs</a>
<h2 class="wp-block-heading">Asia Markets Today</h2>
On Tuesday, Japan&#8217;s Nikkei 225 closed 0.67% higher at 38,567.50, led by gains in the Real Estate, Banking, and Textile sectors.
Australia&#8217;s S&amp;P/ASX 200 was down 0.08% at 8,541.30, led by losses in the Utilities, Financials and Healthcare sectors.
India&#8217;s Nifty 50 was down 0.37% at 24,853.40, and the Nifty 500 declined 0.49% to 22,981.50.
China&#8217;s Shanghai Composite was down 0.04% at 3,387.40, and Shanghai Shenzhen CSI 300 slid 0.09% to 3,870.38.
Hong Kong&#8217;s Hang Seng closed the session 0.34% lower at 23,980.30.
<h2 class="wp-block-heading">Eurozone at 06:00 am ET</h2>
The European STOXX 50 index was down 1.27%.
Germany&#8217;s DAX index declined 1.25%.
France&#8217;s CAC 40 fell 1.05%.
U.K.&#8217;s FTSE 100 index traded lower by 0.47%.
European stocks fell as Iran-Israel tensions escalated, fueling fears of broader conflict and inflation from rising oil prices. Most STOXX 600 sectors declined, led by banks, while energy gained.
<h2 class="wp-block-heading">Commodities at 06:00 am ET</h2>
Crude Oil WTI was trading higher by 1.38% at $71.23/bbl, and Brent was up 1.47% at $74.31/bbl.
Oil prices rose amid ongoing Iran-Israel tensions, though no production losses have been reported. Markets remain volatile as concerns over disruptions at the Strait of Hormuz persist.
Natural gas rose 1.25% to $3.795.
Gold traded lower by 0.33% to $3,406.45, Silver rose 0.62% to $36.675, and Copper fell 0.37% to $4.8182.
<h2 class="wp-block-heading">U.S. Futures</h2>
At 06:00 am ET, the Dow Jones futures fell 0.62%, the S&amp;P 500 declined 0.60%, and the Nasdaq 100 was down 0.61%.
<h2 class="wp-block-heading">Forex</h2>
At 06:00 am ET, the U.S. Dollar Index gained 0.02% to 98.16, USD/JPY was up 0.02% to 144.76, and USD/AUD declined 0.09% to 1.5308.
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets In Red, Oil Spikes On Geopolitical Tensions - Global Markets Today While US Slept

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the financial sector.
<h3 class="wp-block-heading">Ellington Credit Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 16.70%</li>
<li>UBS analyst Douglas Harter maintained a Neutral rating and raised the price target from $5.25 to $5.5 on June 10, 2025. This analyst has an accuracy rate of 68%.</li>
<li>JMP Securities analyst Mikhail Goberman reiterated a Market Perform rating on April 19, 2024. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On May 20, Ellington Credit posted downbeat quarterly earnings</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0617">latest EARN news.</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0617"><img loading="lazy" decoding="async" width="922" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17051955/image-256.png" alt="" class="wp-image-951890" style="width:615px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17051955/image-256.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17051955/image-256-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17051955/image-256-768x705.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Two Harbors Investment Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 16.61%</li>
<li>RBC Capital analyst Kenneth Lee maintained a Sector Perform rating and cut the price target from $13 to $12 on May 28, 2025. This analyst has an accuracy rate of 66%.</li>
<li>UBS analyst Douglas Harter maintained a Buy rating and increased the price target from $12 to $13 on May 1, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: On May 6, TWO Harbors Investment priced its $100 million public offering of 9.375% senior notes due 2030.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest TWO <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0617">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0617"><img loading="lazy" decoding="async" width="908" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17052030/image-257.png" alt="" class="wp-image-951893" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17052030/image-257.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17052030/image-257-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17052030/image-257-768x704.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">MFA Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFA#NYSE">MFA</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 15.13%</li>
<li>RBC Capital analyst Kenneth Lee maintained a Sector Perform rating and cut the price target from $12 to $10 on May 28, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Bose George maintained an Outperform rating and lowered the price target from $12.5 to $12 on May 8, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On June 12, MFA Financial announced a dividend of 36 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0617">MFA news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0617"><img loading="lazy" decoding="async" width="907" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17052103/image-258.png" alt="" class="wp-image-951894" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17052103/image-258.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17052103/image-258-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17052103/image-258-768x704.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45948410/5-stocks-in-the-spotlight-from-wall-streets-most-accurate-analysts-last-week-5">5 Stocks In The Spotlight From Wall Street&#8217;s Most Accurate Analysts Last Week</a> </li>
</ul>
Photo via Shutterstock

Earnings

Long Ideas

Pre-Market Outlook

Trading Ideas

EARN

Wall Street's Most Accurate Analysts Weigh In On 3 Financial Stocks With Over 15% Dividend Yields

Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.53) by 30.19 percent. This is a 42.31 percent decrease over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $57.93 million which beat the analyst consensus estimate of $56.12 million by 3.24 percent. This is a 2.09 percent decrease over sales of $59.17 million the same period last year.

Earnings Beats

VNCE

Vince Holding Q1 EPS $(0.37) Beats $(0.53) Estimate, Sales $57.93M Beat $56.12M Estimate

Kirkland's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIRK#NASDAQ">KIRK</a>) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.47) by 14.89 percent. This is a 20.59 percent increase over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $81.50 million which missed the analyst consensus estimate of $85.60 million by 4.79 percent. This is a 11.17 percent decrease over sales of $91.75 million the same period last year.

Earnings Misses

KIRK

Kirkland's Q1 Adj. EPS $(0.54) Misses $(0.47) Estimate, Sales $81.50M Miss $85.60M Estimate

Contracts

MIND

MIND Technology's Seamap Unit Has Entered Into A Collaboration Agreement With GWL Overseas Ltd. For The Further Development, Promotion And Production Of Gwl's Floatseis Data Acquisition System

Offerings

Redwire Announces Pricing Of Upsized Public Offering Of 15,525,000 Shares At $16.75 Per Share

Lifecore Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has signed a new 10-year commercial manufacturing and supply agreement with a key existing customer. This represents the latest agreement signed between the two companies to support the advancement of a novel ophthalmic therapeutic through clinical development and onto the market.
"In outlining our growth strategy for the coming years, we have stressed the importance of our pipeline of late-stage customer projects that are nearing potential commercialization in the mid-term. The signing of this long-term commercial supply agreement with one of those customers is a critical step on our path to recognizing impactful commercial manufacturing revenue from this longstanding relationship," said Paul Josephs, chief executive officer of Lifecore. "We are committed to supporting our customer as they advance this program toward the market with the potential to make a positive impact on the lives of patients."
In conjunction with the commercial manufacturing and supply agreement, Lifecore has also signed a multi-million-dollar statement of work detailing a range of fill and finish CDMO services that will further advance this program towards potential regulatory approval and commercialization. Under the terms of this new statement of work, Lifecore will be responsible for manufacturing a variety of batches of the drug candidate, including multiple Process Performance Qualification (PPQ) batches.

Comments

Smurfit WestRock

空売り

Smurfit WestRock (NYSE:SW) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル